Clinical Trial Update: PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC [Phase 2]

View source ↗

Summary

A Phase 2 trial update investigates a PD-1 inhibitor given concurrently with chemotherapy as neoadjuvant therapy for triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN